-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] At the end of April, the National Medical Insurance Administration and other two departments issued the "Notice on Improving the National Organization of Drugs (Insulin Special) Centralized Procurement and Use of Supporting Measures", requiring the selected products of insulin centralized procurement to be selected in each provin.
The centralized procurement platform for high-level pharmaceuticals is linked to the Intern.
In November 2021, the results of the sixth batch of centralized drug procurement organized by the state - insulin special procurement results were releas.
42 insulin products were selected through bidding, with an average price reduction of 4
It is expected to save 9 billion yuan per ye.
The selected products are both imported and domest.
The domestic pharmaceutical companies involved include Gan & Lee Pharmaceuticals, United Laboratories, Tonghua Dongbao, Hefei Tianmai, Sunshine Pharmaceuticals, Wanbang Biochemical, Hisun Pharmaceuticals, and multinational pharmaceutical companies include Novo Nordisk, Elixir Lai, Baitong Poland, Sanofi,e.
The implementation of this centralized procurement is related to the well-being of the 10 million insulin patients across the count.
According to the implementation schedule of the Internet in Hainan, Tibet, Liaoning, Fujian, Shandong, Liaoning and other places, it is basically concentrated in M.
At present, the centralized insulin procurement in Tibet, Tianjin and other places has been implement.
Among them, on May 1, 2022, the sixth batch of nationally organized centralized drug procurement (insulin special project) was officially launched in Tianj.
Tianjin has also become the first landing city for this round of insulin centralized procureme.
The Tianjin Pharmaceutical Purchasing Center recently issued the "Instructions on Doing a Good Job in the Sixth Batch of Nationally Organized Drugs Concentrated Procurement (Insulin Special) and Us.
The document shows that pharmaceutical institutions have been able to use the Tianjin Pharmaceutical Purchasing Application Platform to select the price according to the selected pri.
Procurement will be implemented for the sixth batch of nationally selected resul.
It is reported that the purchase demand of Tianjin in the first year is about 6 milli.
From now on, more than 1 million diabetic patients in the city will be able to use cheap insul.
If it is estimated based on the monthly use of three 189 medicines for centralized purchase, without medical insurance reimbursement, the patient's annual drug cost can be reduced to less than 700 yuan, and the average daily cost is less than 2 yu.
Insulin is regarded as an effective treatment for reducing hyperglycemia, and it is continuously improved and optimiz.
Compared with human insulin (second-generation insulin), insulin analogs (third-generation insulin) are more convenient to use and saf.
But before, due to the higher price of the third-generation insulin, its application range is not as good as that of the second-generation insul.
Judging from the official selection results of the sixth batch of national procurement, domestic varieties including third-generation insulin and second-generation insulin have a high bid-winning rate through large price cu.
Among them, Tonghua Dongbao occupies a large share of second-generation insulin, with a total demand of 339 million, accounting for The second generation accounted for 378% of the overall demand; Gan and Lee Pharmaceuticals accounted for a larger share of the third generation insulin, with a total demand of 16 million, accounting for 39% of the third generation overall dema.
The industry believes that after the implementation of centralized procurement, more patients will use the third-generation insulin with high quality and low price, which is conducive to promoting the upgrading of insulin in clinical applicati.
At the same time, since the pressure of price reduction by local pharmaceutical companies is lower than that of multinational pharmaceutical companies, it is expected to further accelerate domestic substituti.
Data show that in 2020, Novo Nordisk, Sanofi, Gan & Lee Pharmaceuticals, e.
will occupy the main share of China's insulin market, accounting for 47%, 19%, and 13% respective.
With the implementation of this special centralized procurement of insulin, local pharmaceutical companies may further increase the market share of insul.
Among them, Tonghua Dongbao once stated in the announcement that this centralized procurement will help the company to further expand the sales of related products, especially insulin analog products, accelerate product access, increase market share, and enhance the company's brand influence It has a positive impact on its strength and future long-term developme.
The centralized procurement platform for high-level pharmaceuticals is linked to the Intern.
In November 2021, the results of the sixth batch of centralized drug procurement organized by the state - insulin special procurement results were releas.
42 insulin products were selected through bidding, with an average price reduction of 4
It is expected to save 9 billion yuan per ye.
The selected products are both imported and domest.
The domestic pharmaceutical companies involved include Gan & Lee Pharmaceuticals, United Laboratories, Tonghua Dongbao, Hefei Tianmai, Sunshine Pharmaceuticals, Wanbang Biochemical, Hisun Pharmaceuticals, and multinational pharmaceutical companies include Novo Nordisk, Elixir Lai, Baitong Poland, Sanofi,e.
The implementation of this centralized procurement is related to the well-being of the 10 million insulin patients across the count.
According to the implementation schedule of the Internet in Hainan, Tibet, Liaoning, Fujian, Shandong, Liaoning and other places, it is basically concentrated in M.
At present, the centralized insulin procurement in Tibet, Tianjin and other places has been implement.
Among them, on May 1, 2022, the sixth batch of nationally organized centralized drug procurement (insulin special project) was officially launched in Tianj.
Tianjin has also become the first landing city for this round of insulin centralized procureme.
The Tianjin Pharmaceutical Purchasing Center recently issued the "Instructions on Doing a Good Job in the Sixth Batch of Nationally Organized Drugs Concentrated Procurement (Insulin Special) and Us.
The document shows that pharmaceutical institutions have been able to use the Tianjin Pharmaceutical Purchasing Application Platform to select the price according to the selected pri.
Procurement will be implemented for the sixth batch of nationally selected resul.
It is reported that the purchase demand of Tianjin in the first year is about 6 milli.
From now on, more than 1 million diabetic patients in the city will be able to use cheap insul.
If it is estimated based on the monthly use of three 189 medicines for centralized purchase, without medical insurance reimbursement, the patient's annual drug cost can be reduced to less than 700 yuan, and the average daily cost is less than 2 yu.
Insulin is regarded as an effective treatment for reducing hyperglycemia, and it is continuously improved and optimiz.
Compared with human insulin (second-generation insulin), insulin analogs (third-generation insulin) are more convenient to use and saf.
But before, due to the higher price of the third-generation insulin, its application range is not as good as that of the second-generation insul.
Judging from the official selection results of the sixth batch of national procurement, domestic varieties including third-generation insulin and second-generation insulin have a high bid-winning rate through large price cu.
Among them, Tonghua Dongbao occupies a large share of second-generation insulin, with a total demand of 339 million, accounting for The second generation accounted for 378% of the overall demand; Gan and Lee Pharmaceuticals accounted for a larger share of the third generation insulin, with a total demand of 16 million, accounting for 39% of the third generation overall dema.
The industry believes that after the implementation of centralized procurement, more patients will use the third-generation insulin with high quality and low price, which is conducive to promoting the upgrading of insulin in clinical applicati.
At the same time, since the pressure of price reduction by local pharmaceutical companies is lower than that of multinational pharmaceutical companies, it is expected to further accelerate domestic substituti.
Data show that in 2020, Novo Nordisk, Sanofi, Gan & Lee Pharmaceuticals, e.
will occupy the main share of China's insulin market, accounting for 47%, 19%, and 13% respective.
With the implementation of this special centralized procurement of insulin, local pharmaceutical companies may further increase the market share of insul.
Among them, Tonghua Dongbao once stated in the announcement that this centralized procurement will help the company to further expand the sales of related products, especially insulin analog products, accelerate product access, increase market share, and enhance the company's brand influence It has a positive impact on its strength and future long-term developme.
